Research ArticleInflammation, Immunopharmacology, and Asthma
The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
Luca Piali, Sylvie Froidevaux, Patrick Hess, Oliver Nayler, Martin H. Bolli, Eva Schlosser, Christopher Kohl, Beat Steiner and Martine Clozel
Journal of Pharmacology and Experimental Therapeutics May 2011, 337 (2) 547-556; DOI: https://doi.org/10.1124/jpet.110.176487
Luca Piali
Sylvie Froidevaux
Patrick Hess
Oliver Nayler
Martin H. Bolli
Eva Schlosser
Christopher Kohl
Beat Steiner
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleInflammation, Immunopharmacology, and Asthma
The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
Luca Piali, Sylvie Froidevaux, Patrick Hess, Oliver Nayler, Martin H. Bolli, Eva Schlosser, Christopher Kohl, Beat Steiner and Martine Clozel
Journal of Pharmacology and Experimental Therapeutics May 1, 2011, 337 (2) 547-556; DOI: https://doi.org/10.1124/jpet.110.176487
Research ArticleInflammation, Immunopharmacology, and Asthma
The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation
Luca Piali, Sylvie Froidevaux, Patrick Hess, Oliver Nayler, Martin H. Bolli, Eva Schlosser, Christopher Kohl, Beat Steiner and Martine Clozel
Journal of Pharmacology and Experimental Therapeutics May 1, 2011, 337 (2) 547-556; DOI: https://doi.org/10.1124/jpet.110.176487
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement